A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence

Weber, Jeffrey; Grob, Jean-Jaques; Margolin, Kim A; Ascierto, Paolo A; Sznol, Mario; Ott, Patrick A; Lejeune, Chantal; de Pril, Veerle; Ruisi, Mary M; Hodi, F Stephen

doi:10.1186/2051-1426-3-S2-P166

Article metrics
Last updated: Thu, 25 Apr 2024 14:54:39 Z

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence

Access & Citations

1527

Article Accesses
0

Web of Science
5

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.